About GMI

GMI (Ganoderma microsporum immunomodulatory protein)is the culmination of 30 years of biotech research in Taiwan.
Here, we witness the metamorphosis of GMI, from the legendary medicinal roots of ganoderma, a traditional Chinese medicine, to the scientifically proven effectiveness of GMI today.

GMI Certification
The beginning Ganoderma microsporum, a new type of ganoderma native to Taiwan. GMI, the first ganoderma ingredient to achieve western medicine standards after 30 year of joint industrial, government and academic research.
Discovery of Ganoderma microsporum
In 1982, an unassumingly small ganoderma mushroom is found on a piece of willow tree, named Ganoderma microsporum due to is small spore size (compared with other types of ganoderma.
Published in Mycotaxon as a new type of ganoderma in 1989.
Discovery of GMI
Utilizing bioinformatics and gene cloning, GMI was found by cross examining the generic data of dozens of types of ganoderma in 2005.
Brand new exclusive ingredient
In 2009, the mass production and functional analyses of GMI was completed with the help of an yeast recombinant protein production platform. Database registry and structural patents for GMI were also obtained during the same year.
Basic research From genetic sequencing to the molecular structure; from quality and safety to efficacy. Decades of research stands the test of time.
Sequence to structure
structure to function: GMI has a similar 3D structure to human antibodies. The protein crystal shows a unique tetramer configuration.
Stable structure
The protein structure of GMI is highly rigid and able to maintain stability in different types of solutes.
Clear structure to ensure quality
the clear structure of GMI forms the basis for its effectiveness, the assurance of quality for GMI derived products.
Safety assessment-genetic toxicity
  • Testing site: Level
  • GLP-compliant

Results of bacterial reverse mutation test (OECD test no. 471), in vitro chromosomal aberration test (OECD test no. 473) and mammalian erythrocyte micronucleus test (OECD test no. 474) were all negative.
Safety assessment- bio-compatibility
  • Testing site: SuperLab
  • GLP-compliant

Cytotoxicity test for mouse fibroblasts (ISO10993-5): half maximal inhibitory concentration (IC50) > 94 μg/mL
Safety assessment-acute toxicity
  • Testing site: SuperLab
  • GLP-compliant

No observed adverse effect level (NOAEL) of acute dermal toxicity test (OECD test no. 402) > 38 μg/kg body weight.
Safety assessment-acute toxicity
  • Testing site: Industrial Technology Research Institute (ITRI)

NOAEL level for mouse IV injection > 2000 μg/kg body weight.
Safety assessment-90 days toxicity
  • Testing site: Pharmaron Beijing
  • GLP-compliant

NOAEL for rat feed > 100 μg/kg body weight.
Safety assessment- teratogenicity test (fetus mutation)
  • Testing site: Pharmaron Beijing
  • GLP-compliant

NOAEL for rat feed > 100 μg/kg body weight.

The primary amino acid sequence of GMI dictates its tertiary protein properties. 44.1% of essential amino acids are found in this short 111 amino acid single chain protein.

Applied research The name of GMI is derived from scientific data. GMI has been proven to not only improve immune imbalances, but also treat cancer, aging and infection.
The National Cancer Institute (NCI) of the US National Institute of Health (NIH) report on the effects of GMI in 60 types of human cancer cell lines:
GMI can eliminate cancer cells and inhibit cancer cell growth.
In the report, for each type of cancer, the right side line indicates the cancer-killing effect of GMI, while the left side line indicates the cancer-inhibitory effect of GMI.
GMI has different levels of inhibitory effects on leukemia, non-small cell lung cancer, colorectal cancer, CNS cancer, malignant melanoma, ovarian cancer, kidney cancer, prostate cancer and breast cancer.
The median lethal concentration (LC50) of GMI is around 20 μg/mL of GMI in cancer cells.
Mass production Innovative molecular engineering using recombinant yeast to produce GMI at an industrial scale. The fist ganoderma ingredient to achieve western medicine standards.
Research roadmap

GMI listed on the Taiwan FDA food ingredient

GMI completed review for GRAS by US FDA

GMI found to calm cytokine storms during severe infections

GMI listed on the International Nomenclature of Cosmetic Ingredients (INCI), #35581

GMI listed on the US FDA New Dietary Ingredient (NDI), #1133

GMI found to repair neurons in the brain

Analytical method of GMI passes TAF-ISO17025 accreditation

Taiwan Ministry of Economic Affairs granted GMI as a potential new drug candidates

US NIH reports GMI can effectively treat 60 types of common cancer cells

3D structure of GMI registered in Protein Data Bank

GMI found to treat lung cancer cells

GMI registered in NIH database

GMI discovered in Ganoderma microsporum using bioinformatics and genetic engineering

New type of ganoderma officially named “Ganoderma microsporum”

A new type of ganoderma mushroom discovered in Taiwan


about the book GMI: A novel molecule for biomedical applications - the blue ocean of oncology therapeutics

There are many lab-claimed anti-cancer ingrediants, but few that make it all the way to your doctor’s prescription, because it is very hard to achieve the trifecta of “safety”, “effectiveness”and “mass production”.

Yet today, GMI, an immunomodulatory protein originating from Ganoderma, has achieved just that! A US National Institute of Health (NIH) study has shown the suppressive effects of GMI on 9 types of cancer; Research teams from the National Taiwan University, National Yang-Ming University, Chung Shan Medical University, Taipei Medical University and others have also shown GMI, even at very small doses, to be effective against many different types of cancer, including drug resistant cancer cells and even cancer stem cells. GMI has even been shown to boost the effectiveness and reduce the negative side effects of chemotherapy, targeted therapy and immunotherapy.

Most importantly, all these anti-cancer effects can be safely realized on people.

Patent roadmap
Contact us

8F.-1, No. 12, Ln. 270, Sec. 3, Beishen Rd., Shenkeng Dist., New Taipei City 222 , Taiwan (R.O.C.)